Validation of a Single-sample Urinary C-peptide Creatinine Ratio As a Reproducible Alternative to Serum C-peptide in Patients with Type 2 Diabetes
Overview
Affiliations
Aims: Serum C-peptide can be used in Type 2 diabetes as a measure of endogenous insulin secretion, but practicalities of collection limit its routine clinical use. Urine C-peptide creatinine ratio is a non-invasive alternative that is stable for at least 3 days at room temperature in boric acid preservative. We aimed to assess the utility of urine C-peptide creatinine ratio in individuals with Type 2 diabetes as an alternative to serum C-peptide.
Methods: We assessed, in 77 individuals with Type 2 diabetes, the reproducibility of, and correlations between, fasting and postprandial urine C-peptide creatinine ratio and serum C-peptide, and the impact of renal impairment (estimated glomerular filtration rate < 60 ml min(-1) 1.73 m(-2)) on these correlations.
Results: Urine C-peptide creatinine ratio was at least as reproducible as serum C-peptide [fasting coefficient of variation mean (95% CI): 28 (21-35)% vs. 38 (26-59)% and 2-h post-meal 26 (18-33)% vs. 27 (20-34)%. Urine C-peptide creatinine ratio 2 h post-meal was correlated with stimulated serum C-peptide, both the 2-h value (r = 0.64, P < 0.001) and the 2-h area under the C-peptide curve (r = 0.63, P < 0.001). The association seen was similar in patients with and without moderate renal impairment (P = 0.6).
Conclusions: In patients with Type 2 diabetes, a single urine C-peptide creatinine ratio is a stable, reproducible measure that is well correlated with serum C-peptide following meal stimulation, even if there is moderate renal impairment. Urine C-peptide creatinine ratio therefore has potential for use in clinical practice in the assessment of Type 2 diabetes.
Exploring the potential role of C-peptide in type 2 diabetes management.
Lin Y, McCrimmon R, Pearson E Diabet Med. 2025; 42(3):e15469.
PMID: 39797595 PMC: 11823364. DOI: 10.1111/dme.15469.
Reintar S, Pochhacker M, Obermayer A, Eberhard K, Zirlik A, Verheyen N Nutrients. 2023; 15(9).
PMID: 37432211 PMC: 10181310. DOI: 10.3390/nu15092073.
Irilouzadian R, Afaghi S, Esmaeili Tarki F, Rahimi F, Malekpour Alamadari N Endocrinol Diabetes Metab. 2023; 6(3):e413.
PMID: 36808709 PMC: 10164436. DOI: 10.1002/edm2.413.
Zhou W, Li J, Yuan X, Wang W, Zhou H, Zhang H Front Endocrinol (Lausanne). 2022; 13:1052794.
PMID: 36465621 PMC: 9712960. DOI: 10.3389/fendo.2022.1052794.
Pappachan J, Sunil B, Fernandez C, Lahart I, Ashraf A touchREV Endocrinol. 2022; 18(1):2-9.
PMID: 35949364 PMC: 9354948. DOI: 10.17925/EE.2022.18.1.2.